Abstract
HDAC inhibitors show great promise for the treatment of cancer. As part of a broader effort to explore the SAR of HDAC inhibitors, synthesis, biological evaluation, and molecular docking of novel Ugi products containing a zinc-chelating moiety are presented. One compound shows improved inhibitory potencies compared to SAHA, demonstrating that hindered lipophilic residues grafted on the peptide scaffold of the α-aminoacylamides can be favorable in the interaction with the enzyme.
Lingua originale | Inglese |
---|---|
pagine (da-a) | 2776-2785 |
Numero di pagine | 10 |
Rivista | Journal of Medicinal Chemistry |
Volume | 52 |
Numero di pubblicazione | 9 |
DOI | |
Stato di pubblicazione | Pubblicato - 14 mag 2009 |